Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -64.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $3M | $371166 | $157516 | $19M | $67M | $99M | $183M | $186M | $171M | $60M |
| Enterprise Value | $-1357144 | $-751510 | $-4280834 | $-2662484 | $17M | $64M | $92M | $167M | $162M | $158M | $57M |
| P/E Ratio → | -0.21 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | 91.13 | 157.88 | 128.17 |
| P/B Ratio | 0.08 | 0.20 | 0.02 | 0.01 | 1.40 | 2.20 | 2.25 | 2.62 | 2.11 | 10.85 | 5.40 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | 79.28 | 145.88 | 121.54 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | — | — | — | — | -525.8% | -1139.5% | -3615.0% |
| Net Profit Margin | — | — | — | — | — | — | — | — | -483.6% | -1133.5% | -3630.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.2% | -64.2% | -49.8% | -50.6% | -81.4% | -87.0% | -50.5% | -25.9% | -19.0% | -91.5% | -103.9% |
| ROA | -55.5% | -55.5% | -42.8% | -41.7% | -67.2% | -73.0% | -44.4% | -24.4% | -17.9% | -68.2% | -83.3% |
| ROIC | -54.4% | -54.4% | -41.4% | -49.5% | -67.1% | -75.6% | -49.4% | -28.4% | -24.2% | -172.5% | -99.8% |
| ROCE | -53.0% | -53.0% | -41.6% | -54.8% | -79.9% | -87.6% | -52.7% | -28.3% | -20.7% | -89.4% | -100.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.02 | 0.01 | 0.00 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.28 | -0.20 | -0.13 | -0.09 | -0.15 | -0.22 | -0.27 | -0.82 | -0.28 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -500.13 | -627.36 | -82.10 | -754.05 | -974.52 | -678.06 | -255.12 | -252.33 | -251.97 |
Net cash position: cash ($4M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.55 | 6.55 | 7.42 | 4.81 | 4.76 | 6.13 | 6.47 | 11.02 | 33.41 | 4.98 | 3.44 |
| Quick Ratio | 6.55 | 6.55 | 7.42 | 4.81 | 4.76 | 6.13 | 6.47 | 11.02 | 33.41 | 5.00 | 3.49 |
| Cash Ratio | 6.38 | 6.38 | 7.06 | 4.60 | 4.46 | 5.92 | 6.35 | 10.89 | 33.33 | 4.94 | 3.37 |
| Asset Turnover | — | — | — | — | — | — | — | — | 0.02 | 0.06 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | 9.13 | 52.14 | 221.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $538915 | $116353 | $28849 | $209523 | $204980 | $177340 | $175953 | $151147 | $104061 | $94789 |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EOCN stock.
Eocene Ltd.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Eocene Ltd.'s return on equity (ROE) is -64.2%. The historical average is -60.5%.
Based on historical data, Eocene Ltd. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Shrinking liquidity against persistent losses
Deep Book Discount Reflects Capital Erosion
Based on EOCN's reported figures, the 0.08 price-to-book ratio sits far below typical biotech levels, yet with negative earnings the P/E of -0.21 offers no meaningful earnings anchor for valuation.
The 0.08 P/B suggests the market prices EOCN at a small fraction of its book equity, which appears to reflect skepticism about the durability of remaining net assets given continued losses. With P/E negative and EV/EBITDA and P/FCF unavailable, valuation rests almost entirely on book value, and investors should monitor whether that book base continues to erode. Without a revenue base or positive cash flow, growth-based or cash-flow-based multiples cannot be meaningfully applied.
Persistently Negative Returns Deepen Recently
As reported in financial statements, EOCN's ROE moved from -9.1% in 2024Q2 to -20.4% in 2026Q2, while ROIC stayed negative across all ten quarters, indicating capital is being consumed rather than compounded.
The widening ROE in recent quarters, despite a shrinking equity base, suggests losses are growing faster than the denominator is shrinking, which warrants further investigation into the cost trajectory. ROIC remaining negative throughout the period indicates the company has not yet converted invested capital into any operating return. These patterns appear consistent with an early-stage developer whose returns depend on future commercialization that the reported data does not yet show.
Headline Current Ratio Masks Shrinking Cushion
According to reported quarterly figures, the current ratio of 4.16 in 2026Q2 remains high, but it is down from 9.02 in 2025Q1 and sits against cash of only $3.0M and ongoing cash burn.
The current ratio has compressed substantially over the past year, which may indicate that current assets are being drawn down faster than current liabilities are growing. The 4.16 figure reflects a small liability base, so it may overstate true flexibility relative to absolute cash. Under a stress scenario, the limited cash buffer against operating outflows would likely constrain runway, though the reported data does not disclose the timing of any financing.
Negligible Debt Keeps Solvency Risk Low
Based on EOCN's reported balance sheet, debt-to-equity of 0.01 and total debt of $129.0K indicate that leverage is immaterial, so solvency pressure stems from losses rather than borrowing.
The near-zero leverage means interest coverage of -27.21 reflects negative operating earnings rather than debt service strain, so the coverage metric carries little weight for this business. Refinancing or covenant risk appears minimal given the absence of meaningful borrowings in the reported data. The more relevant pressure point is equity erosion, which affects the company's capacity to absorb further losses without new capital.
Current Ratio Misleads on Real Flexibility
The current ratio is most commonly misapplied to pre-revenue developers, where it reflects a small liability base and overstates flexibility while cash has fallen by more than two-thirds since 2024Q3.
For a pre-revenue company, the current ratio captures the size of short-term liabilities relative to current assets, but it does not measure how long those assets can fund operating losses. A better lens is months of runway, calculated from cash divided by average quarterly operating cash burn. Using that approach would likely show a shorter effective cushion than the headline 4.16 suggests, and investors should monitor the reported cash trajectory closely.